Filing Flows › TG Therapeutics (TGTX) › Product revenue
TG Therapeutics (TGTX) Product revenue by quarter
TG Therapeutics' Product revenue was $236M in Q2 2026 (second quarter 2026), +17% from Q1 2026. Over the last 7 quarters it ranged from $107M (Q4 2024) to $236M (Q2 2026).
| Quarter | Product revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $236M | +17% | +70% |
| Q1 2026 | $201M | +6% | +68% |
| Q4 2025 | $189M | +19% | +76% |
| Q3 2025 | $159M | +15% | — |
| Q2 2025 | $139M | +16% | — |
| Q1 2025 | $120M | +11% | — |
| Q4 2024 | $107M | — | — |
Q2 2026 at a glance
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' Product revenue?
TG Therapeutics' Product revenue was $236M in Q2 2026 (second quarter 2026), +17% from Q1 2026.
How has TG Therapeutics' Product revenue changed?
Over the last 7 quarters it ranged from $107M (Q4 2024) to $236M (Q2 2026).